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Objective: To evaluate the effectiveness and adverse events of non-pharmacological 
interventions in patients with exacerbation of COPD. 
Patients and Methods: We searched Embase, MEDLINE, Cochrane databases, Scopus and 
clinicaltrials.gov from database inception to January 2, 2019, for randomized controlled trials 
(RCTs) that enrolled adults with exacerbation of COPD and evaluated the effect of non-
pharmacological interventions on clinical outcomes and/or lung function. 
Results: We included 30 RCTs with 2,643 participants. Improvement in 6-minute walking 
distance was associated with resistance training (WMD (weighted mean difference) 74.42; 
95% CI: 46.85 to 101.99), pulmonary rehabilitation (WMD 20.02; 95% CI: 12.06 to 28.67), 
whole body vibration (WMD 89.42; 95% CI: 45.18 to 133.66) and transcutaneous electrical 
nerve stimulation (WMD: 64.54; 95% CI: 53.76 to 75.32). Improvement of quality of life was 
associated with resistance training (WMD: 18.7; 95% CI: 5.06 to 32.34), combined breathing 
technique and range of motion exercises (WMD: 14.89; 95% CI: 5.30 to 24.50), whole body 
vibration (WMD: -12.02; 95% CI: -21.41 to -2.63) and intramuscular vitamin D (WMD: -
4.67; 95% CI: -6.00 to -3.35 at the longest follow-up). Oxygen titration with a target oxygen 
saturation range of 88%-92% was associated with reduced mortality compared with high flow 
oxygen (OR: 0.36; 95% CI: 0.14 to 0.88). All findings were based on low strength of 
evidence. 
Conclusion: In patients hospitalized for exacerbation of COPD, exercise interventions and 
pulmonary rehabilitation programs may ameliorate functional decline.  Oxygen should be 
titrated with a target oxygen saturation of 88-92% in these patients. 







Exacerbations of chronic obstructive pulmonary disease (COPD) are the leading cause of 
increased mortality and morbidity in COPD. 1-3 Antibiotics, systemic corticosteroids and 
short-acting bronchodilators are the cornerstones of the management of exacerbations of 
COPD but non-pharmacological interventions may also play a role.4 There is growing 
awareness that careful oxygen titration in an acute setting with a target oxygen saturation rate 
(to avoid oversupply of oxygen) may be beneficial not only in COPD patients with known 
hypercapnic respiratory failure but in COPD patients in general.5  Chest physiotherapy is 
frequently used to clear pulmonary secretions from the lungs, but there is uncertainty about 
its effectiveness to improve health outcomes. 3 Pulmonary rehabilitation is an effective 
intervention to improve health outcomes in patients with stable COPD or patients who have 
stabilized after an episode of COPD exacerbation.6 More recently, pulmonary rehabilitation 
in patients hospitalized for exacerbation of COPD has become a focus of interest, in 
particular as a potential tool to ameliorate deconditioning. Malnutrition is relatively common 
among patients with COPD.7 8 During an exacerbation, factors such as loss of appetite and 
reduced dietary intake, physical inactivity, inflammation, hypoxaemia and the use of systemic 
corticosteroids may induce or accelerate weight loss and muscle wasting. Nutritional 
assessment and therapy during exacerbations of COPD is recommended,9 but the impact of 
nutritional interventions during exacerbations on health outcomes is uncertain. There are 
other non-pharmacological interventions such as whole body vibration training and 
transcutaneous electrical nerve stimulation which only relatively recently have been 
considered for treatment during exacerbations of COPD. The objective of this systematic 
review was to evaluate the impact of non-pharmacological interventions compared with usual 





The systematic review was guided by a study protocol (PROSPERO Identifier: 
CRD42018111609, https://effectivehealthcare.ahrq.gov/products/copd/protocol), which we 
developed with input from clinical and methodological experts and professional 
organizations, and was generated from an AHRQ report 
(https://effectivehealthcare.ahrq.gov/products/copd/research). 
 
Date sources and searches 
We searched Embase, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
MEDLINE Daily, MEDLINE, Cochrane Central Registrar of Controlled Trials, Ovid 
Cochrane Database of Systematic Reviews, and Scopus) and clinicaltrials.gov from database 
inception to January 2, 2019. We also searched grey literature and conducted reference 
mining. The databases, grey literature, and detailed search strategy are listed in eTable 1 in 
the Supplement.   
  
Study selection 
We included randomized controlled trials (RCTs) published in English that enrolled patients 
18 years and older with exacerbation of COPD. Studies had to compare a non-
pharmacological intervention with placebo, a sham procedure, or management without 
intervention in outpatients, hospitalized patients or patients attending an emergency 
department. We excluded studies conducted in the intensive care unit (ICU), chronic 
ventilator unit, or respiratory care unit and studies that assessed invasive and non-invasive 
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mechanical ventilation in any study setting. Studies had to assess at least one of the following 
outcomes: repeat exacerbations; dyspnea; mortality; quality of life; hospital readmission; ICU 
admission; functional capacity (timed walking tests, endurance tests); need for intubation; 
symptoms; lung function; adverse event (AE). 
 
Independent reviewers, working in pairs, screened the titles and abstracts of all citations and 
the full text of studies included by either reviewer. Disagreements were resolved through 
consensus in consultation with a third reviewer. 
 
Data extraction and risk of bias assessment 
We developed a standardized data extraction form to extract study characteristics. Reviewers 
worked independently to extract study details. Data extraction and risk of bias assessment 
were completed by pairs of independent reviewers. We used the Cochrane Collaboration’s 
Risk of Bias tool to assess risk of bias at a study and outcome level.10 
 
Data Synthesis and Analysis 
We summarized RCTs by type of intervention, comparator, and outcomes. Statistical 
analyses were based on the intention-to-treat principle. We extracted or calculated the odds 
ratio (OR) and corresponding 95-percent confidence intervals for binary outcomes. For 
continuous outcomes, we calculated the standardized mean difference (SMD) when different 
measures for the same outcome were reported (e.g. different quality of life measurement 
tools). We also standardized the direction of the measures with higher scores representing 
better outcomes when different measurement tools were used. We calculated weighted mean 
difference (WMD) when the included studies used the same outcome measure. Hospital 
readmissions and repeat exacerbations were based on number of persons with at least one 
7 
 
event (binary outcome) as well as the number of events, for which the rate ratio was 
calculated by dividing the incidence rate of events in the intervention group by the incidence 
in the control group. For AEs, we also calculated the rate ratio. We used the definition of 
serious AEs listed by the original studies. Mortality and repeat exacerbation were reported as 
effectiveness outcomes and not reported as serious AEs in this review. AEs were categorized 
(eTable 2 in the Supplement). 
Interventions labelled as pulmonary rehabilitation in original studies were classified as 
aerobic and/or resistance exercise interventions if they only contained an exercise component 
and were not multi-faceted interventions. 
We narratively synthesized crossover RCTs as they had significant reporting and 
methodological weaknesses, such as missing data and failure to control within-individual 
difference. 
We used the DerSimonian and Laird (D-L) random effect method to combine direct 
comparisons between treatments if the number of studies included in the analysis was larger 
than 3.6,11 We used the fixed effect method based on the Mantel and Haenszel method due to 
instability of between-study variance, when the number of studies in a meta-analysis was 3 or 
less.12  We were unable to statistically evaluate publication bias due to the small number of 
studies included in each meta-analysis. 13 All statistical analyses were conducted using 
Stata/SE version 15.1 (StataCorp LLC, College Station, TX). 
 
Grading the Strength of Evidence 
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The strength of evidence (SOE) for each outcome was designated as high, moderate, low, or 
‘insufficient evidence to estimate an effect’ (definitions appear in eTable 3 in the 
Supplement).14 
Results 
Thirty citations that represented 30 unique RCTs15-44 and 2,643 participants were included in 
the analysis (eFigure 1 in the Supplement)  All trials were conducted in patients with 
moderate or severe exacerbation of COPD. 28 studies16-18,20-44 were conducted in hospitalized 
patients, one19 in both outpatients and hospital settings, and one in an ambulance.15 Studies 
were conducted in the Canada (3), Europe (13), Asia (9), Australia (4), Africa (8), and South 
America (1). One study was a crossover RCT.28 Average length of the intervention was 11.33 
days, and the mean reported follow-up time was 4.46 months. Details of the interventions 
used in each study can be found in eTable 4 in the Supplement. 
The overall risk of bias in the included studies was intermediate to high due to unclear 
sequence generation (36.67%), unclear allocation concealment (60.00%), and high risk or 
unclear risk of incomplete outcome data (60.00%) (eTable 5  in the Supplement). 
Results for primary and secondary effectiveness outcomes can be found in Table 1 and 
eTable 6 in the Supplement respectively. AEs and withdrawals are listed in eTable 7 in the 
Supplement.  
 
Airway clearance techniques 
We identified seven RCTs16,19,21,23,28,29,34 with airway clearance technique interventions using 
either breathing technique,16,21,28 vibration or percussion,19,23,29  or positive expiratory 
pressure43compared with management without these interventions. Breathing technique was 
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associated with reduced hospital readmissions at the longest follow-up (N=2; Rate Ratio: 
0.91; 95% CI: 0.83 to 0.99, I2=79.5%, Low SOE)21,28 but not with any other outcomes. No 
association of vibration/percussions19,23,29 or positive expiratory pressure34 with any 
effectiveness outcomes was observed. Serious AEs reported in the positive expiratory 
pressure group included 9 cases of serious clinical deterioration (all-causes) and 3 cases of 
acute sputum retention.34  
 
Exercise 
Eight RCTs evaluated exercise interventions including resistance training (of which two used 
upper and lower limb resistance training18,39 and one used lower limb resistance training 
only41), aerobic exercise17,20,27,40 and a combination of resistance training and aerobic 
exercise38 compared with management without these interventions. The SOE for all outcomes 
was low. 
Resistance training was associated with better quality of life (WMD: 18.70; 95% CI: 5.06 to 
32.34),39 reduced dyspnea (N=1; WMD: -2.11; 95% CI: -3.50 to -0.72),39 and longer 6-
minute walking distance (N=2; WMD: 74.42; 95% CI: 46.85 to 101.99; I2=95.42%),18,41 but 
not with other outcomes or number of withdrawals. Aerobic exercise was associated with 
improved dyspnea (N=1; WMD: 7.20; 95% CI: 4.53 to 9.87) and quality of life (WMD: 
38.00; 95% CI: 24.51 to 51.49),17 number of steps walked per day (N=1; WMD: 663.03; 95% 
CI: 496.34 to 829.72)40 and endurance based on a 30-second sit-to-stand test (N=1; WMD: 
4.63; 95% CI: 2.54 to 6.72)40 at the end of intervention but worse dyspnea (N=1; WMD: 
1.20; 95% CI: 0.33 to 2.07).20 One RCT38 compared combined aerobic and resistance 
training, using a low intensity and a moderate to high-intensity exercise group, vs 
management without aerobic and resistance training. Independent of intensity, combined 
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aerobic and resistance training was not significantly associated with 3-minute walking 
distance, upper limb muscle strength, forced expiratory volume in 1 second (FEV1) % 
predicted and number total of AEs.38  
 
Breathing technique and range of motion exercises combined 
A combination of breathing technique and range of motion exercises was associated with 
improvement in quality of life (N=1; WMD: 14.89; 95% CI: 5.30 to 24.50, Low SOE),39 but 
not dyspnea or FEV1 % predicted,  compared with management without breathing technique 
and range of motion exercises in one RCT.39   
 
Multi-faceted pulmonary rehabilitation program 
Four RCTs20,22,24,26,31 compared pulmonary rehabilitation vs management without pulmonary 
rehabilitation. The SOE for all outcomes was low. Pulmonary rehabilitation was associated 
with a longer 6-minute walking distance (N=3; WMD: 20.02; 95% CI: 12.06 to 28.67; 
I2=79.08%),22,26,31 decreased dyspnea (based on a numeric scale) at the end of the 
intervention (N=2; SMD: 0.66; 95% CI: 0.31 to 1.00; I2=89.21%) 26,31 but not at the longest 
follow-up, and decreased cough (N=1; WMD: -2.00; 95% CI: -2.98 to -1.02).31 Risk of 
readmission was similar in both groups (N=1; HR: 1.19, 95% CI: 0.90 to 1.60).24  There was 
no significant difference between the intervention and control group in serious AEs, total 
number of AEs, withdrawals, and withdrawals due to AEs.  
 
Whole body vibration 
Whole body vibration training was compared with management without whole body 
vibration training in one RCT,25 which found that the intervention was associated with higher 
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quality of life (WMD: -12.02; 95% CI: -21.41 to -2.63; I2=N/A, Low SOE) and a longer 6-
minute walking distance (WMD: 89.42; 95% CI: 45.18 to 133.66, Low SOE).  
 
Transcutaneous Electrical Nerve Stimulation 
One RCT33 evaluated Transcutaneous Electrical Nerve Stimulation (TENS) vs management 
without TENS. TENS was associated with longer 6-minute walking distance (WMD: 64.54; 
95% CI: 53.76 to 75.32, Low SOE) but not with dyspnea, FEV1 and number of withdrawals. 
 
Oxygen 
We identified 3 RCTs with an oxygen intervention; one trial assessed supplemental oxygen 
vs supplemental air during mobilization with a walking aid,44 one RCT evaluated titrated vs 
high flow oxygen;15  and one RCT compared vs manual oxygen titration.30 Supplemental 
oxygen during mobilization with a walking aid (gutter frame or rollator) was not significantly 
associated with mortality, 30-day hospital readmissions, dyspnea, number of withdrawals, 
and total number of AEs, compared with supplemental air. Hypoxemia at rest was not a 
requirement for inclusion in this study (paCO2 ranged from 72-80 mmHg at baseline), and 
oxygen levels were not measured during mobilization. One RCT compared titrated oxygen 
(with a target oxygen saturation between 88% and 92% delivered by nasal prongs) vs high 
flow oxygen (8-10 liters/min, administered by a non-rebreather face mask)15 in patients 
transported to hospital via ambulance. Titrated oxygen was associated with reduced mortality 
(OR: 0.36; 95% CI: 0.14 to 0.88, Low SOE). Approximately 70% of deaths occurred within 
the first five days of admission for both treatment arms. Automated oxygen saturation 
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titration compared with manual titration was not significantly associated with mortality and 
other effective outcomes in another RCT.30 
 
Dietary interventions 
Each of the following interventions was assessed by one RCT: caloric supplement vs usual 
diet;37 caloric and a protein supplement vs placebo (non-caloric fluid, vanilla flavored 
water);43 and high fat low carbohydrate diet vs usual diet42; and omega-3 fatty acid enriched 
diet vs usual diet.32 There were no significant associations between any of the interventions 
and effectiveness outcomes and AEs.  
Two studies35,36 evaluated the effectiveness of vitamin D (taken orally or given as an 
intramuscular injection) compared with placebo. Vitamin D was associated with better 
quality of life based on the St George's Respiratory Questionnaire at the end of the 
intervention (N=1; WMD: -1.96; 95% CI: -2.89 to -1.03, Low SOE),35 and at the longest 
follow-up (N=1; WMD: -4.67; 95% CI: -6.00 to -3.35, Low SOE).35 No statistical difference 
was found in the number of withdrawals due to AEs.  
 
Discussion 
In this systematic review with meta-analyses, exercise, multi-faceted pulmonary 
rehabilitation programs, whole body vibration and transcutaneous electrical nerve stimulation 
(TENS) were associated with improved functional outcomes (primarily based on the 6-
minute waking distance) in patients hospitalized for moderate or severe exacerbation of 
COPD. Resistance training, combined breathing technique and range of motion exercises, 
whole body vibration and intramuscular vitamin D were associated with better quality of life. 
Oxygen titration with a target oxygen saturation range of 88%-92% was associated with 
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reduced mortality compared with high flow oxygen. Seventeen of the 30 studies (57%) 
reported AEs or number of withdrawals. Reported AEs were generally mild. We found no 
significant differences in AEs and serious AEs between non- pharmacological therapies and 
control groups. There was a lack of trials that compared pharmacological with non-
pharmacological therapies or combinations thereof (other than multi-faceted pulmonary 
rehabilitation programs). 
Breathing technique was the only airway clearance technique associated with an improved 
clinical outcome (reduced hospital readmissions at the longest follow-up). A previous 
Cochrane review from 2012 reported a reduction in the need for ventilatory support (invasive 
or non-invasive), length of time on ventilatory support and length of hospital stay associated 
with airway clearance teachniques.45 This was based on studies conducted in patients 
requiring non-invasive ventilation,46,47 patients treated in the ICU,48 and patients treated for 
exacerbation of chronic bronchitis (rather than COPD),49 all of which were excluded in our 
review. Our review did, however, include five new RCTs not previously included in the 
Cochrane review.16,34,50-52 It is possible that patients with an exacerbation at the most severe 
end of the spectrum, requiring ventilatory support and/or treatment in the ICU stand to 
benefit the most from airway clearance techniques.  
 
Our review showed evidence of benefits from exercise during hospitalization for moderate to 
severe exacerbation of COPD using resistance or aerobic exercise for functional outcomes 
(primarily 6-minute walking distance). These benefits were visible in exercise only 
interventions as well as in multifaceted pulmonary rehabilitation programs, which we 
analyzed separately. The American Thoracic Society/European Respiratory Society 
guidelines published in 2017 made a conditional recommendation (very low quality of 
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evidence) to not initiate pulmonary rehabilitation during hospitalization for exacerbation of 
COPD.53 This was based on a meta-analysis of two RCTs54,55 that showed that patients with 
exacerbation of COPD who started pulmonary rehabilitation in hospital had increased 
mortality (50 deaths in 210 patients in the intervention group, 32 deaths in 205 patients in the 
control group; RR 1.54, 95% CI 1.03 to 2.29). The results were driven by a trial of 
rehabilitation commenced within 48 hours of hospital admission in 389 patients with 
exacerbations of different chronic respiratory conditions (patients with exacerbation of COPD 
constituted 82% of the cohort) that found an increase in mortality in the intervention group at 
one year (49 deaths in196 patients in the intervention group, 31 deaths in 193 patients in the 
control group; OR 1.74, 95% CI 1.05 to 2.88).54 Given the potential of pulmonary 
rehabilitation commenced in hospital to ameliorate the functional decline associated with 
exacerbation of COPD, high quality RCTs with careful safety monitoring of patients to 
determine its potential benefits and harms are needed to determine the optimal timing of 
pulmonary rehabilitation.  
 
One trial found reduced mortality with oxygen titration using a target oxygen saturation 
between 88% and 92% compared with high flow oxygen (8-10 liters/min) during ambulance 
transport to the hospital in cohort in which hypercapnic respiratory failure was highly 
prevalent.15 A target oxygen range of 88%-92% is now the accepted standard of practice in 
patients with exacerbation of COPD in many settings, supported by British guidelines.56 It 
remains unclear whether such a target oxygen range is only beneficial in patients at risk of 
hypercapnic respiratory failure or whether patients with exacerbation of COPD but absence 




High-Flow Nasal Cannula is a relatively recently introduced system delivering heated 
humidified air-oxygen mixture with the ability to deliver a high fraction of inspired oxygen 
and generate a low level of positive pressure. It is currently unclear whether High-Flow Nasal 
Cannula is associated with improved clinical outcomes compared with conventional oxygen 
therapy or non-invasive ventilation in exacerbation of COPD.57,58 
 
For most interventions, only one RCT was available per outcome which limits inferences 
from the quantitative synthesis. Failure to detect statistical significance for most of the 
outcomes may have resulted from type II error. All studies were conducted in hospitalized 
patients with moderate to severe exacerbation of COPD, and the results may therefore not be 
applicable to patients with milder forms of exacerbation of COPD treated in an outpatient 
setting. As we excluded studies conducted in an intensive care setting and/or in patients 
requiring ventilator support, some of our findings may not be extrapolated to the most 
severely sick patients with exacerbation of COPD. The included studies were overall at high 
risk of bias. The evaluation of AEs was limited as the majority of the included studies (43%) 
did not evaluate or report AEs.   
 
The treatment options of whole body vibration, transcutaneous electrical nerve stimulation 
(TENS) and vitamin D, which showed improved functional outcomes and betters quality of 
life respectively in our review, need to be assessed in large high quality RCTs to inform 
recommendations about these treatments. Such literature (e.g., on vitamin D) is notorious for 
contradictory findings over time. Trials are needed that compare pharmacological with non-





The findings of the systematic review and meta-analyses highlight that some non-
pharmacologic interventions hold promise for improving clinically important outcomes in 
particular they might improve functional capacity and thus mitigate the deconditioning 




AE: adverse event 
CI: confidence interval 
COPD: chronic obstructive pulmonary disease 
FEV1: forced expiratory volume in 1 second 
ICU: intensive care unit 
N: number 
OR: odds ratio 
RCT: randomized controlled trial 
SOE: strength of evidence 
TENS: transcutaneous electrical nerve stimulation 
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Table 1. Primary Effectiveness Outcomes in Adult Patients with Exacerbation of COPD 














without airway clearance 
techniques 
Mortality 
End of intervention   
OR: 0.97; 
95%CI: 0.06 
to 16.20, I2= 
N/A 











to 1.49, I2= 
N/A 











End of Intervention 
WMD: 0.40; 
95%CI: -0.24 
to 1.04, I2= 
N/A 
1 RCT28 with 
59 patients 
High ROB 





































0.91; 95% CI: 
0.83 to 0.99, 
I2=79.5% 


















End of Intervention 
SMD: 0.15; 
95%CI: -0.29 
to 0.60, I2= 
0.00% 
2 RCTs23,29 with 
80 patients 
High ROB 










to 0.25, I2= 
N/A 
1 RCT23 with 50 
patients 
High ROB 





End of Intervention       
WMD: 56.20; 
95%CI: -8.18 
to 120.58, I2= 
N/A 








techniques using positive 
expiratory pressure 
versus management 
without positive airway 
clearance techniques 
Mortality 
End of Intervention   
OR: 1.00; 
95%CI: 0.06 
to 16.48, I2= 
N/A 











to 6.00, I2= 
N/A 










End of Intervention 
WMD: 0.40; 
95%CI: -0.16 
to 0.96, I2= 
N/A 













to 1.06, I2= 
N/A 








Exacerbation    
End of Intervention       
OR: 1.00; 
95%CI: 0.06 
to 16.48, I2= 
N/A 








Exacerbation   
Longest Followup       
Rate Ratio: 
1.05; 95% 
0.69 to 1.59, 
I2= N/A 







QoL(SGRQ) WMD: -1.50; 1 RCT34 with 92 Severe Low SOE 
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Longest Followup 95%CI: -5.99 
to 8.99, I2= 
N/A 
patients imprecision supporting no 
difference 
6MWD 



























Exercise using resistance 






95% CI: 0.01 
to 4.81, I2= 
N/A 








Dyspnea   
(Numeric Scale; 
Modified Borg)                 
End of Intervention 
WMD: -2.11; 
95% CI: -
3.50 to -0.72, 
I2= N/A 
1 RCT39 with 60 
patients 
Intermediate 






End of Intervention 
WMD: 18.70; 
95% CI: 5.06 
to 32.34, I2= 
N/A 
1 RCT39 with 60 
patients 
Intermediate 







Longest Followup          
 
OR: 1.23; 
95% CI: 0.35 
to 4.31, I2= 
N/A 








End of Intervention       
WMD: 74.42; 
95%CI: 46.85 
to 101.99, I2= 
95.42% 








Exercise using aerobic 




End of Intervention 
OR: 1.00; 
95% CI: 0.06 
to 17.02, I2= 
N/A 











End of Intervention 
WMD: 7.20; 
95% CI: 4.53 
to 9.87, I2= 
N/A 














95% CI: 0.33 
to 2.07, I2= 
N/A 















N/A     









QoL(CAT)                  






1 RCT20  with 29 
patients 
Intermediate 









95% CI: 0.33 
to 6.77, I2= 
N/A 
1 RCT20 with 29 
patients 
Intermediate 






0.96; 95% CI: 
0.39 to 2.37, 
I2= N/A 
1 RCT20 with 29 
patients 
Intermediate 






Exacerbation   
OR: 0.74; 
95% CI: 0.22 
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Exercise using combined 
aerobic + resistance 
training versus 
management without 
exercise training  
Low Intensity Exercise 
Group  vs management 
without exercise training 
3-minute Walking 
Distance Test  
End of Intervention 
SMD: 0.40; 
95% CI: -
0.50 to 1.30, 
I2=N/A 







Exercise using combined 
aerobic + resistance 
training versus 
management without 
exercise training  
Moderate-to-High 
Intensity Exercise Group  
vs management without 
exercise training 
3-minute Walking 
















Breathing technique and 












End of Intervention 
WMD: 1.15; 
95% CI: -
0.61 to 2.91, 
I2= N/A 
1 RCT39 with 60 
patients 
Intermediate 







End of Intervention 
WMD: 14.89; 
95% CI: 5.30 
to 24.50, I2= 
N/A 



















End of Intervention 
OR: 3.26; 
95% CI: 0.13 
to 81.98, 
I2=N/A 
1 RCT22 with 97 
patients 
High ROB 







End of Intervention       
WMD: -0.50; 
95% CI: -
3.01 to 2.06,  
I2=N/A 
1 RCT26 with 94 
patients 
High ROB 










0.48 to 0.56, 
I2=N/A 











End of Intervention 
SMD: 0.66; 
95% CI: 0.31 
to 1.00, 
I2=89.21% 











Longest Followup                     
WMD: 0.20; 
95% CI: -
0.69 to 0.29, 
I2= N/A 
1 RCT22 with 97 
patients 
High ROB 






at 30 days 
OR: 0.65; 
95% CI: 0.26 
to 1.60, I2= 
N/A 
1 RCT22  with 
97 patients 
High ROB 





0.60; 95% CI: 
0.31 to 1.15, 
I2= N/A 
1 RCT22  with 
97 patients 
High ROB 





Ratio: 1.19;  
95% CI: 0.90 
to 1.60, I2= 
1 RCT 24 with 
320 patients 
High ROB 







6MWD                    















Whole body vibration 
training during AECOPD 
versus management 
without whole body 
QoL(SGRQ)                          
End of Intervention   
WMD: -
12.02; 95% 
CI: -21.41 to 
-2.63, I2= N/A 









6MWD                     















nerve stimulation (TENS) 








End of Intervention   
WMD: -0.23; 
95% CI: -
0.57 to 0.11,  
I2= N/A 
1 RCT33 with 82 
patients 
High ROB 




6MWD                    
End of Intervention    
WMD: 64.54; 
95%CI: 53.76 
to 75.32, I2= 
N/A 








Gutter Frame with 
Supplemental Oxygen vs. 
Gutter Frame with 
Supplemental Air 
Dyspnea   
(Numeric: Borg 
Dyspnea Scale) 
End of intervention    
WMD: 0.80; 
95% CI: -
0.90 to 2.50, 
I2=N/A 
1 RCT44 with 60 
patients 
High ROB 







95% CI: 0.06 
to 16.76, 
I2=N/A 
1 RCT44 with 60 
patients 
High ROB 








95% CI: 0.41 
to 6.47,  
I2=N/A  
1 RCT44 with 60 
patients 
High ROB 






vs. Rollator with 
Supplemental Air 
Dyspnea   
(Numeric: Borg 
Dyspnea Scale) 
End of Intervention    
WMD: -0.90; 
95% CI: -
2.35 to 0.58, 
I2=N/A  
 
1 RCT44 with 60 
patients 
High ROB 






0 cases in 
both groups  
1 RCT44 with 60 
patients 
High ROB 








95% CI: 0.41 
to 6.47,  
I2=N/A 
1 RCT44 with 60 
patients 
High ROB 









95% CI: 0.14 
to 0.88, 
I2=N/A  I2 








Need for Intubation 
Longest Followup 
OR: 0.13; 
95% CI:  0.02 
to 1.00, 
I2=N/A 
1 RCT15 with 
214 patients 
High ROB 




Titrated oxygen vs free 
flow oxygen 
Mortality 
End of Intervention  
OR: 1.00; 
95% CI: 0.06 
to 16.93, 
I2=N/A   
1 RCT30 with 50 
patients  
Intermediate 





Need for intubation 
End of intervention 
OR: 3.12; 
95% CI: 0.12 
to 80.39, 
I2=N/A 
1 RCT30 with 50 
patients  
Intermediate 











95% CI: 0.27 
to 3.66, 
I2=N/A 
1 RCT30 with 50 
patients  
Intermediate 









95% CI: 0.53 
to 4.98, 
I2=N/A 
1 RCT30 with 50 
patients  
Intermediate 






End of Intervention 
OR: 3.12; 
95% CI: 0.12 
to 80.39, 
I2=N/A 
1 RCT30 with 50 
patients  
Intermediate 





Dietary intervention using 
a caloric supplement 
during AECOPD versus 
usual diet 
Mortality 
End of Intervention   
OR: 0.81; 
95% CI: 0.05 
to 14.28, I2= 
N/A 
1 RCT37 with 31 
patients 
High ROB 




































Dietary intervention using 








score while eating)  
End of Intervention 
WMD: 0.5; 
95% CI: -
1.14 to 2.14, 
I2= N/A 
1 RCT43 with 47 
patients 
High ROB 




Dietary intervention using 
omega-3 fatty acid 
versus usual diet 
QoL (CAT)  
End of Intervention 
WMD: 0.00; 
95% CI: -
3.46 to 3.46, 
I2= N/A 







Need for Intubation 
End of Intervention 
OR: 0.18; 
95% CI: 0.01 
to 4.04, I2= 
N/A 










End of intervention  
WMD: 0.00; 
95% CI: -
0.55 to 0.55, 
I2= N/A 







Dietary intervention using 
vitamin D during 





to 9.88, I2= 
N/A 
1 RCT35 with 70 
patients 
High ROB 












2 RCTs35 36 with 
160 patients 
High ROB 










to 0.63, I2= 
N/A 
1 RCT35  with 
70 patients 
High ROB 





End of Intervention 
WMD: -1.96; 
95%CI: -2.89 
to -1.03, I2= 
N/A 












6.00 to -3.35, 
I2= N/A 








6MWD = six minute walking distance; CAT = COPD assessment test; CI = confidence interval; CRQ = chronic respiratory 
disease questionnaire; EQ-5D = EuroQol 5 dimensions; ICU = intensive care unit; MMRC = modified medical research 
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council scale; MRC = medical research council scale; N/A = not applicable; OR = odds ratio; QoL = quality of life; RCT = 
randomized controlled trial; ROB = risk of bias; SGRQ = St. George respiratory questionnaire; SMD = standardized mean 
difference; SOE = strength of evidence; VAS = visual analog scale; WMD = weighted mean difference 
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